Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HC...

Descripción completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Autores principales:	Lu, Liangjun, Pilot-Matias, Tami J., Stewart, Kent D., Randolph, John T., Pithawalla, Ron, He, Wenping, Huang, Peggy P., Klein, Larry L., Mo, Hongmei, Molla, Akhteruzzaman
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 2004
Materias:	Antiviral Agents
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415624/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15155230/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.6.2260-2266.2004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!